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Abstract
Background: Alcohol dependence is a significant and costly problem in the UK yet only 6% of people a year
receive treatment. Current service provision based on the treatment of acute episodes of illness and emphasising
personal choice and motivation results in a small proportion of these patients engaging with alcohol treatment.
There is a need for interventions targeted at the population of alcohol dependent patients who are hard to
engage in conventional treatment. Assertive Community Treatment (ACT), a model of care based on assertive
outreach, has been used for treating patients with severe mental illnesses and presents a promising avenue for
engaging patients with primary alcohol dependence. So far there has been little research on this.
Methods/Design: In this single blind exploratory randomised controlled trial, a total of 90 alcohol dependent
participants will be recruited from community addiction services. After completing a baseline assessment, they will
be assigned to one of two conditions: (1) ACT plus care as usual, or (2) care as usual. Those allocated to the ACT
plus care as usual will receive the same treatment that is routinely provided by services, plus a trained key worker
who will provide ACT. ACT comprises intensive and assertive contact at least once a week, over 50% of contacts in
the participant’s home or local community, and comprehensive case management across social and health care,
for a period of one year. All participants will be followed up at 6 months and 12 months to assess outcome post
randomisation. The primary outcome measures will be alcohol consumption: mean drinks per drinking day and
percentage of days abstinent measured by the Time Line Follow Back interview. Secondary outcome measures will
include severity of alcohol dependence, alcohol related problems, motivation to change, social network
involvement, quality of life, therapeutic relationship and service use. Other outcome variables are treatment
engagement including completion of assessment, detoxification and aftercare.
Discussion: Results of this trial will help clarify the potential beneficial effects of ACT for people with alcohol
dependence and provide information to design a definitive trial.
Trial registration number: ISRCTN: ISRCTN22775534
Keywords: assertive outreach, alcohol dependence, case management, substance use treatment, assertive commu-
nity treatment
Background
The use of alcohol is one of the leading contributors to
ill-health and premature deaths, and is the third leading
cause of disability in Europe [1]. In England approxi-
mately 4% of the population aged 16-65 are alcohol
dependent [2], but access to services is limited with
large regional variations. The cost of alcohol misuse to
the UK economy is estimated to be £25 bn [3] and over
£200 m is spent annually on alcohol treatment in Eng-
land. People with alcohol dependence who are not
engaged in treatment use disproportionate levels of
health, social, and criminal justice services, often
through unplanned care [4].
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The Alcohol Harm Strategy for England highlighted
the need to improve treatment services for people with
alcohol dependence, particularly those with more com-
plex needs [5] and Models of Care for Alcohol Misusers
(MoCAM) supported the development of specialist
delivered interventions for this population [6]. Current
alcohol service provision focuses on discrete, time-lim-
ited episodes of intervention, typically of a few weeks to
a few months duration and emphasises personal choice
and motivation. However studies have shown that
engagement is often problematic [7,8], and despite con-
ventional treatment approximately one third of alcohol
dependent patients continue to drink heavily and have
poor long term outcomes [9]. For this group of patients,
alcohol dependence is a chronic, relapsing disorder
[10-12] and in typical practice, treatment often involves
multiple episodes extending over many years.
A parallel has been drawn between the management of
chronic relapsing alcohol dependence and the manage-
ment of various chronic physical and mental health pro-
blems [13]. In these a ‘chronic disease management’
approach has become an accepted clinical model in some
chronic conditions such as diabetes. This involves ongoing
care extending over a prolonged period to alter the long
term trajectory of the disease. In adult mental health care,
ACT is an extensively researched and widely used model
of care for treating unmotivated and difficult to engage
patients with severe and enduring mental illness. It
emphasises active engagement over an extended period
[14,15]. Key features of effective ACT include: (i) rapid
access to services, (ii) a small caseload, (iii) a high ratio of
community to office-based appointments, (iv) assertive
engagement (e.g. with multiple attempts) and (v) a shared
care approach, with care coordinators working within a
multidisciplinary team that meets frequently [16,17].
In the United States ACT has been shown to be effec-
tive in reducing the number and length of admissions to
hospital and achieving stable accommodation. It
improves patients’ satisfaction and motivation for treat-
ment [18,19], and is effective in retaining patients in
care [20,21]. European studies, however, have been less
supportive of ACT and no advantage over usual care
has been found for clinical or social outcomes, although
it has been demonstrated to improve client engagement
and satisfaction with services [22]. One reason identified
for the lack of ACT superiority observed in the UK is
that usual care for severe mental illness duplicates sev-
eral of the key elements of ACT [16,22]. No such over-
lap is apparent in the current treatment of alcohol
dependence. Some of the features of ACT have already
been individually applied to the treatment of alcohol
dependence and found to improve aspects of outcome.
For example, [23] used home visits as part of an after-
care package and found that these increased the
likelihood of treatment completion, while a randomised
controlled trial found that a flexible and extended
approach to aftercare increased the time to first drink
and reduced the severity of relapse [24,25]. Most
recently a pilot of assertive engagement methods
resulted in a significantly greater number of patients
completing treatment and entering aftercare [7]. How-
ever, the potential benefits of elements of ACT in
patients with alcohol dependence but without severe
mental illness remain unclear as are the specific aspects
of the model that might apply to this disorder.
In this article we describe the methods of an explora-
tory randomised controlled trial (RCT) that is designed
to test the feasibility of implementing ACT for people
with chronic relapsing alcohol dependence. It aims to
identify both optimal and problematic elements of ACT
specific to this population and to establish the potential
effect size of ACT versus standard care and evaluate
‘proof of principle’.
Methods/Design
Overview
The Assertive Community Treatment for Alcohol
Dependence (ACTAD) study is a two centre single blind
randomised controlled trial of assertive outreach plus
care as usual (CAU) compared with a CAU control con-
dition for people with alcohol dependence. The primary
analysis will be intention-to-treat.
Intervention
Assertive community treatment intervention
ACT was originally developed for patients with psycho-
tic disorders and has become an established model of
care for this population in the US and UK. Since this
intervention has never been used for people with pri-
mary alcohol dependence, the research team will imple-
ment an ACT model taking into account the original
model and recent research identifying effective elements
in UK studies. A treatment manual will be developed by
the research team together with experts in the provision
of ACT and incorporating existing research evidence.
The ACT intervention will comprise the following:
(i) Maximum caseload of 15 ACT patients per ACT
practitioner
(ii) Input from a multidisciplinary team (including
psychiatrists, substance misuse specialists)
(iii) Regular contact (minimum of once a week; 50% of
contacts outside of the service settings, either in the
patients’ home or neighbourhood; short frequent con-
tacts rather than long complex contacts will be
encouraged).
(iv) Assertive engagement - persistent and repeated
attempts to contact, emphasis on maintaining contact
and building relationships
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(iii) Focus on both health and social care needs -
including accommodation, leisure, occupation, and phy-
sical and mental health
(iv) Flexibility - practitioners should work flexibly with
patients’ goals even when these are peripheral to the
addiction.
(v) Openness - practitioners are explicit about their
goals both in care planning and in visits.
(viii) Going out of your way - stepping outside of pro-
fessional roles and going the extra mile for patients.
(ix) Extended care - provided for a prolonged period
of 1 year.
Training
The training will comprise a three day workshop and a
one day clinical placement. The workshop will provide
specialist addiction clinicians with information about
ACT, its’ history, implementation in mental health and
the ACTAD trial. Following the workshops each practi-
tioner will attend a one day placement with a mental
health assertive outreach team. They will shadow a
member of staff including attending community and
home visits with patients and have the opportunity to
ask questions regarding the day to day practice of pro-
viding ACT. A final training day will focus on ACT
practice in addictions. A minimum of three members of
staff at each site will receive the training.
Control intervention
The participants in the control condition will receive
CAU, as this provides an appropriate comparison with
routine clinical practice and will address the issue of
whether ACT plus CAU is more effective than CAU
alone. CAU components will be actively recorded as
part of the trial but are likely to include allocation of a
keyworker when one becomes available, with subsequent
contact as required. All contact is usually conducted at
the service via an appointment based system. Partici-
pants will receive a full assessment of alcohol, social and
physical health needs, and a risk assessment. CAU
focuses primarily on alcohol use and promoting absti-
nence and relapse prevention. It includes access to med-
ical detoxification, psychological interventions focused
on drinking behaviour and available aftercare as
required. CAU may also include input from specialists
in addictions psychiatry, clinical psychology and social
work where available. Patients are most often signposted
to other relevant agencies when these services are not
directly provided by the addiction treatment service.
Aftercare will typically be provided outside the commu-
nity addiction services. The majority of patients are dis-
charged to primary care within 12 weeks of being
allocated a keyworker unless there are significant risks
identified. Failure to attend appointments also results in
discharge from the service. To establish the variability of
CAU for a full-scale trial, interviews will be undertaken
with team leaders at each study site and an additional
four national sites examining care pathways.
Intervention fidelity
Each ACT practitioner will participate in a training
course involving a series of workshops and placements
prior to delivering the intervention to eligible patients.
During the intervention, practitioners are encouraged to
attend monthly supervisory meetings with the research
team during which fidelity will be assessed and the ACT
intervention will be reinforced. In addition, staff provid-
ing care to participants in both arms of the trial will
complete a contact log detailing the care they provide
for each patient following each contact. The log, devel-
oped from a previous study of assertive outreach in the
UK [17], includes details about the mode of contact (i.e.
face to face, telephone), setting, focus of contact, and
the member of staff involved. This will provide a mea-
sure of the care provided to participants in each arm of
the trial.
Participants and baseline recruitment
Potential participants will be identified by staff in parti-
cipating community addiction services. In services oper-
ating a triage or self-referral system, patients presenting
with alcohol problems will be screened by staff on pre-
sentation. In services operating a referral only system,
all referrals will be screened by a member of the clinical
team. The team will identify patients in the first instance
with a primary alcohol disorder, previous contact with
participating addiction services for alcohol dependence,
and no history of violence to treatment staff or risk to
others as determined by registration under the UK
Multi-Agency Public Protection Arrangement (MAPPA).
All patients meeting these criteria will be contacted and
asked if they would like more information about the
research trial and asked for verbal consent to being con-
tacted by a member of the research team.
Research workers will approach patients who have
expressed an interest in the study and invite them to a
meeting in order to discuss the study in detail. At this
meeting the researchers will undertake a full screening of
eligibility. Eligible patients will be given a full description
of the study and provided with a written information
sheet. If willing to participate, they will be invited to sign
the consent form. A baseline interview will then be con-
ducted by the research worker taking between 1-11/2hrs.
Subsequently, the patient will be randomised using a
secure, remote randomisation service independent of the
research team, to either the intervention or control group.
Figure 1 shows a participant flow diagram for the trial,
consistent with the Consolidated Standards of Reporting
Trials (CONSORT) 2010 statement [26]
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Eligibility
Inclusion criteria
i) Age18 years or over
ii) Is able to understand English sufficiently well to
obtain informed consent and complete the assess-
ment instruments
 
 
Baseline assessment 
Randomised 
(n=90) 
Assessed for eligibility (n=…) 
Excluded (n=…) 
Not meeting inclusion criteria (n=…) 
Refused to participate (n=…) 
Other reasons (n=…) 
Allocated to ACT + CAU (n=45) 
 
6 month follow up 
Lost to follow up (give reasons) 
(n=…) 
Discontinued intervention (give 
reasons) (n=…) 
Analysed (n=…) 
Excluded from analysis  
(give reasons) (n=…) 
Allocated to CAU (n= 45) 
 
6 month follow up 
Lost to follow up (give reasons) 
(n=…) 
Discontinued intervention (give 
reasons) (n=…) 
Analysed (n=…) 
Excluded from analysis  
(give reasons) (n=…) 
12 month follow up 
Lost to follow up (give reasons) 
(n=…) 
Discontinued intervention (give 
reasons) (n=…) 
12 month follow up 
Lost to follow up (give reasons) 
(n=…) 
Discontinued intervention (give 
reasons) (n=…) 
Figure 1 Participant flow diagram. The participant flow diagram illustrates randomisation of 90 patients with alcohol dependence to ACT plus
CAU or CAU, consistent with the Consolidated Standards of Reporting Trials (CONSORT) 2010 statement.
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iii) Has attended an NHS Community addiction ser-
vice in either of the participating Trusts for alcohol
dependence on at least one previous occasion in the
last five years
iv) Is alcohol dependent. The Composite Interna-
tional Diagnostic Interview [27] is used to establish
dependence, a diagnosis characterised by craving,
tolerance, a preoccupation with alcohol and contin-
ued drinking in spite of resulting harmful conse-
quences [28].
Exclusion criteria
i) Unable to give informed consent
ii) Is street homeless
iii) Is diagnosed with a psychotic disorder
iv) Is in receipt of assertive outreach services or has
community mental health team (CMHT) input once
or more a month
v) Has a severe cognitive impairment as determined
by Mini Mental State Examination score of ≤ 10 [29]
vi) Has a history of violence to staff or is registered
under MAPPA
Assessments
Baseline assessments
(i) Socio-demographic details - age, sex, ethnicity, mari-
tal status, living arrangement, children, living arrange-
ments of children, education
(ii) Drinking in the previous 90 days - Timeline Fol-
lowback form 90I [30]
(iii) History of drug use - Timeline Followback
(iv) Alcohol related problems - Alcohol Problems
Questionnaire [31]
(v) Severity of alcohol dependence -Severity of Alcohol
Dependence Questionnaire [32]
(vi) Health utility - EQ-5D [33]
(vii) Health Related Quality of life - SF-12 [34]
(viii) Motivation to change - Readiness to Change
Treatment version [35]
(ix) Social network involvement - Important People
and Activities Inventory [36]
(x) Health service utilisation - York Service Use
Questionnaire
Follow up assessments
Six months and 12 months after randomisation, all par-
ticipants will be followed up. A research worker, blind
to treatment allocation, will arrange a convenient time
to meet with the participant in order to complete the
following measures:
(i) Changes in socio-demographic details - change in
relationship status, living arrangements, and living
arrangements of children
(ii) Timeline Followback form 90I
(iii) Drug use in previous 90 days - Timeline
Followback
(iv) Alcohol Problems Questionnaire
(v) Severity of Alcohol Dependence Questionnaire
(vi) EQ-5D
(vii) SF-12
(viii) Readiness to Change
(ix) Important People and Activities Inventory
(x) York Service Use Questionnaire
(xi) Therapeutic relationship - STAR [37]
Randomisation and blinding
Randomisation is performed after the baseline assess-
ment. Randomisation is stratified by severity of alcohol
dependence (< = 30 and > 30), as measured by the
Severity of Alcohol Dependence Questionnaire (SADQ),
and by site. The University of York Trials Unit will per-
form remote randomisation. Confirmation of eligibility,
consent, and baseline data will be obtained prior to ran-
domisation. Research workers conducting follow up
assessments are blind to the allocated intervention. All
possible attempts at maintaining blinding will be
pursued.
Sample size and power calculation
As this study is the first to examine the effect size of
ACT in alcohol dependence, there is no specific study
on which to base the power calculation. In terms of
alcohol consumption a proportional difference between
the groups of 30% would be considered a clinically
important difference. This equates to an effect size dif-
ference of 0.70 similar to the effect sizes found in Pat-
terson et al study [38] and the Cochrane meta-analysis
of ACT [19]. As a pilot study we have employed an
alpha of 0.2 and power of 80%, a sample of 35 in each
group followed-up at 12 months would allow us to
detect an effect size of the order of 0.5, a more conser-
vative estimate of effect than seen in similar studies.
Allowing a loss to follow-up of 25% would suggest we
require 45 in each group, a total of 90 participants. This
number would allow us to estimate the potential effect,
within 80% confidence intervals in order to enable more
formal sample size calculations for a definitive study.
Statistical analysis
The main hypothesis, stated as a null hypothesis, is that
CAU augmented with ACT is no more effective than
CAU in reducing alcohol consumption 12 months after
randomisation. The primary outcome measures will be
alcohol consumption: mean drinks per drinking day and
percentage of days abstinent at 12 months measured
using the Timeline Followback interview. The primary
analysis will be intention-to-treat in which participants
will be analysed as part of their allocated group
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irrespective of the treatment received; this provides the
most rigorous estimate of effectiveness. The primary
outcome measure will be analysed using an analysis of
covariance approach adjusting for known confounding
variables such as baseline mean drinks per drinking day,
age and gender. If the assumptions underlying
ANCOVA are not met transformations will be underta-
ken and if transformations are not viable alternative
non-parametric approaches will be used. In order to
explore the impact of missing data on the primary out-
come measure we will employ multiple imputation tech-
niques and conduct sensitivity analyses to measure any
effect of missing data on reported outcomes.
Continuous secondary measures will be analysed in a
similar manner. Categorical variables will be analysed
using chi-squared statistics and binary outcomes analysed
using logistic regression controlling for known confound-
ing variables. Estimates and the 80% confidence intervals
will be presented. In addition intra-class correlation coef-
ficients relating to therapists will be calculated and esti-
mates of recruitment, engagement in treatment,
retention will be assessed to inform any future study.
Economic evaluation
Resources used in care provision will be recorded on an
individual patient basis by staff providing ACT and
CAU for each patient following every contact and enable
further costing of care provision. The main economic
evaluation will take an NHS perspective, including the
cost of all hospital and community health and social
care services, as recommended by the National Institute
for Health and Clinical Excellence (NICE). A wider per-
spective will also be adopted by measuring and applying
unit costs to contacts with the criminal justice system.
Resource use information will be collected using a mod-
ified version of the York Adult Service Use Schedule.
Unit costs of wider health care utilisation beyond the
trial interventions will be compiled from a variety of
sources including NHS Reference Costs [39] and the
Unit costs of Health and Social Care published by the
Personal Social Services Research Unit (PSSRU) [40].
EQ-5D will be used to estimate Quality Adjusted Life
Years (QALYs) and the changes in QALYs for ACT and
CAU will be combined with cost data to perform an
incremental cost-effectiveness analysis. Patient level cost
and outcome data will be bootstrapped and cost-effec-
tiveness acceptability curves will estimate the probability
that ACT is more cost-effective than CAU over a range
of threshold values at which the decision maker is will-
ing to pay for a QALY.
Process evaluation
Since this is the first time ACT has been provided for
patients with a primary diagnosis alcohol dependence, a
process evaluation will be undertaken. This will explore
the processes through which ACT works in practice,
staff and participant experiences of ACT, and aid in the
identification of optimal and problematic elements of
ACT in this population.
ACT practitioners will complete a case report for each
participant after the 12 month intervention period. The
case reports will detail presenting problems, care pro-
vided over the 12 month period and the main outcomes.
Participants will be purposively sampled to include
positive and negative drinking outcomes such as absti-
nence and no change in drinking, engagement and non-
engagement with the ACT practitioner and intervention,
and positive and negative experiences of providing and
receiving ACT. Each ACT recipient identified will be
invited to take part in a semi-structured interview fol-
lowing their 12 month follow up quantitative interview.
This will explore how the participant came into the
trial, their experience of ACT during the treatment per-
iod including identifying helpful and unhelpful elements,
their perceptions of change during this period, and pro-
blems that have not been addressed.
Participants will also be asked to compare this episode
of care with previous episodes, and identify any other
factors (external to the ACT) that may have had an
impact on their drinking during the intervention period.
Approximately 12 participants will be interviewed across
all three sites. A parallel interview will be undertaken
with the participants’ ACT practitioner. The practitioner
interview will explore the process and content of ACT
care provision from initial presentation following rando-
misation through the 12 month intervention period. As
with the ACT recipient interview, practitioners will be
asked to identify elements of care that have been helpful
or problematic, perceptions of change and areas that
they have been unable to address to date. The partici-
pant and ACT practitioners interviews will form paired
data sets enabling triangulation of data.
Finally, an interview will be undertaken with each of
the ACT practitioners to explore their overall experi-
ence of providing ACT, taking into account all partici-
pants they have provided care for as part of the trial.
These interviews will be analysed in conjunction with
the paired interviews providing further detail on the
process and content of ACT care provision, as well as
differences between individual practitioners and research
sites.
To enhance the understanding of CAU, a further 12
interviews across the sites will be undertaken with parti-
cipants who were randomised to CAU alone. Partici-
pants will purposively sampled using the same criteria
as for participants interviewed in the ACT arm of the
trial. Similarly, the interview will explore how the parti-
cipant came into the trial, their experience of CAU
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during the treatment period including identifying helpful
and unhelpful elements, their perception of change dur-
ing this period, and problems that have not been
addressed. Additionally participants will be asked to
identify any other factors external to CAU that may
have had an impact on their drinking during the study
period.
Ethics
The study protocol was approved by National Research
Ethics Service Committee London - Chelsea (REC num-
ber: 08/H0801/113).
Discussion
ACT has gained wide acceptance in the US and the UK
as a model of care for people with severe and enduring
mental illness. It focuses on the delivery of effective
interventions in addition to addressing the wider social
and health needs of patients through assertive, intensive
and flexible engagement. ACT has been demonstrated
to reduce the frequency and length of psychiatric admis-
sions while increasing social functioning, and proven to
be cost effective for those with long term relapsing
conditions.
UK studies have shown less benefits of ACT over
standard care and it has been suggested that this may
be in part due to the enhanced nature of standard care
in mental health provision. In contrast to care for men-
tal health problems, current provision for alcohol depen-
dence is time-limited and focused on treatment of
alcohol dependence rather than accompanying pro-
blems. Assertive Community Treatment therefore offers
a potential advantages for engaging patients in treat-
ment, delivering effective interventions and maintaining
abstinence over a period of time for those whom current
provision has failed. The ACTAD study is the first clini-
cal trial to examine the role of ACT in treatment of pri-
mary alcohol dependence. Since previous studies of
ACT in mental health have suggested that both treat-
ment fidelity and the level of standard care may be
importance, ACT fidelity will be measured and CAU
will be described. Finally, a comprehensive process eva-
luation will seek to establish application of ACT for
alcohol dependence and issues surrounding implementa-
tion to inform a definitive trial.
Trial status
The trial is currently in the recruitment phase.
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